Isracann Biosciences Stock Total Asset
Isracann Biosciences fundamentals help investors to digest information that contributes to Isracann Biosciences' financial success or failures. It also enables traders to predict the movement of Isracann Pink Sheet. The fundamental analysis module provides a way to measure Isracann Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Isracann Biosciences pink sheet.
Isracann |
Isracann Biosciences Company Total Asset Analysis
Isracann Biosciences' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Isracann Biosciences Total Asset | 4.09 M |
Most of Isracann Biosciences' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Isracann Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Isracann Biosciences has a Total Asset of 4.09 M. This is 99.95% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The total asset for all United States stocks is 99.99% higher than that of the company.
Isracann Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Isracann Biosciences' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Isracann Biosciences could also be used in its relative valuation, which is a method of valuing Isracann Biosciences by comparing valuation metrics of similar companies.Isracann Biosciences is currently under evaluation in total asset category among its peers.
Isracann Fundamentals
| Return On Equity | -2.53 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | 2.16 M | |||
| Shares Outstanding | 175.99 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Price To Book | 9.57 X | |||
| Price To Sales | 8.83 X | |||
| EBITDA | (4.64 M) | |||
| Net Income | (4.69 M) | |||
| Cash And Equivalents | 310.61 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 0.76 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (1.75 M) | |||
| Earnings Per Share | (0.13) X | |||
| Beta | 0.12 | |||
| Market Capitalization | 2.45 M | |||
| Total Asset | 4.09 M | |||
| Z Score | -3.3 | |||
| Net Asset | 4.09 M |
About Isracann Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Isracann Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Isracann Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Isracann Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Isracann Pink Sheet
Isracann Biosciences financial ratios help investors to determine whether Isracann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isracann with respect to the benefits of owning Isracann Biosciences security.